TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BerGenBio ASA ( (BRRGF) ) just unveiled an update.
Oncoinvent ASA has announced a fully underwritten rights issue to raise NOK 130 million, with tradable subscription rights allocated to key insiders and their associates. This financial move aims to support the ongoing development and trials of their innovative cancer treatment, Radspherin®, which has shown promising early clinical efficacy without significant safety concerns.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Their lead product, Radspherin®, targets micro-metastases in the peritoneum post-surgery using radium-224, and is currently undergoing clinical trials in the US and Europe.
Average Trading Volume: 217,315
Current Market Cap: NOK266.7M
For detailed information about BRRGF stock, go to TipRanks’ Stock Analysis page.